Clinical Trial

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Name: Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid — clinical trial record (NCT07210554)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.

Trial Details

NCT Number	NCT07210554
Lead Sponsor	Chengdu Kangnuoxing Biopharma,Inc.
Conditions	Bullous Pemphigoid (BP)
Enrollment	200 participants
Start Date	2025-11-11
Primary Completion	2028-03-27 (estimated)
Study Completion	2028-05-08 (estimated)
Updated on ClinicalTrials.gov	2025-10-07